MPWT
ARQT icon

MassMutual Private Wealth & Trust’s Arcutis Biotherapeutics ARQT Stock Holding History

MassMutual Private Wealth & Trust’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-7
Closed -$165 – 2403
2026
Q1 		$165 Buy
+7
New +$179 ﹤0.01% 2336

Other funds holding ARQT

Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
PL
Perpetual Ltd Sydney, New South Wales, Australia $7B AUM 19.75% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
JAFL
Jay A. Fishman Ltd Troy, Michigan $1.26B AUM 31.39% 1-Year Est. Return
PCM
Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
KCM
Kornitzer Capital Management Shawnee Mission, Kansas $4.79B AUM 30.56% 1-Year Est. Return
Vontobel Holding
Vontobel Holding Zurich, Switzerland $31.4B AUM 31.97% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return

MassMutual Private Wealth & Trust's ARQT Position: Q2 2026 in Review

MassMutual Private Wealth & Trust sold out of Arcutis Biotherapeutics (ARQT) in Q2 2026, closing a stake of 7 shares — an estimated $165 sold.

MassMutual Private Wealth & Trust first reported a position in ARQT in Q1 2026 and held it in 1 quarter. The position peaked at $165 in Q1 2026. 53 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • MassMutual Private Wealth & Trust reported no remaining Arcutis Biotherapeutics position as of Q2 2026 after selling out during the quarter.
  • MassMutual Private Wealth & Trust sold 7 Arcutis Biotherapeutics shares in Q2 2026, an estimated $165.
  • MassMutual Private Wealth & Trust first reported a position in Arcutis Biotherapeutics in Q1 2026 and held it in 1 quarter.
  • MassMutual Private Wealth & Trust's Arcutis Biotherapeutics position peaked at $165 in Q1 2026.
  • 53 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on MassMutual Private Wealth & Trust's 13F filing for Q2 2026, filed 2 Jul 2026.